Acid-Labile Subunit in Growth Hormone Excess and Deficiency in Adults: Evaluation of Its Diagnostic Value in Comparison with Insulin-Like Growth Factor(IGF)-l and IGF-Binding Protein-3

この論文にアクセスする

この論文をさがす

著者

    • FUKUDA Izumi
    • Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women's Medical University
    • HIZUKA Naomi
    • Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women's Medical University
    • ITOH Emina
    • Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women's Medical University
    • YASUMOTO Kumiko
    • Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women's Medical University
    • ISHIKAWA Yukiko
    • Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women's Medical University
    • MURAKAMI Yuko
    • Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women's Medical University
    • SATA Akira
    • Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women's Medical University
    • TAKANO Kazue
    • Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women's Medical University

抄録

In serum, insulin-like growth factors (IGFs) are primarily present as a ∼150 kDa ternary protein complex, which consists of IGFs, IGF binding protein-3 (IGFBP-3), and acid-labile subunit (ALS). Like IGF-I and IGFBP-3, serum levels of ALS depend on growth hormone (GH). To date, the diagnostic relevance of ALS in adult GH deficiency (GHD) has remained uncertain. To clarify the clinical utility of ALS measurement in adults, we measured serum ALS levels in patients with adult GHD or acromegaly. We also measured the levels of serum IGF-I and IGFBP-3 in these patients to compare the utility of ALS with IGF-I and IGFBP-3 as a marker of GH secretion. Serum ALS was measured by radioimmunoassay (RIA) kit, and serum IGF-I and IGFBP-3 were measured by immunoradiometric assay (IRMA) kits in 56 patients with adult GHD (adult-onset (AO)/child-onset (CO), 13/43) and 43 patients with acromegaly. Serum ALS levels were less than 5<sup>th</sup> percentile in 40 of 56 (71%) patients with adult GHD (32/43 (74%) for CO and 8/13 (62%) for AO), and more than 95<sup>th</sup> percentile in 38 of 43 (88%) patients with acromegaly, respectively. Serum IGF-I levels were less than -1.96 SD in 43 of 56 (77%) patients with adult GHD (35/43 (81%) for CO and 8/13 (62%) for AO) and more than +1.96 SD in 42 of 43 (98%) patients with acromegaly, respectively. Serum IGFBP-3 levels were less than -1.96 SD in 51 of 56 (91%) patients with adult GHD (42/43 (98%) for CO and 9/13 (69%) for AO) and more than +1.96 SD in 31 of 43 (72%) patients with acromegaly, respectively. These data suggested that measurement of ALS offers no advantage over measurements of serum IGF-I and IGFBP-3. Furthermore, our results indicate that serum IGFBP-3 is the most suitable marker of GH secretion for adult GHD, especially CO, while IGF-I may be the most useful in acromegaly.

収録刊行物

  • Endocrine journal

    Endocrine journal 49(3), 379-386, 2002-06-01

    一般社団法人 日本内分泌学会

参考文献:  26件中 1-26件 を表示

被引用文献:  1件中 1-1件 を表示

各種コード

  • NII論文ID(NAID)
    10008701736
  • NII書誌ID(NCID)
    AA10901436
  • 本文言語コード
    ENG
  • 資料種別
    NOT
  • ISSN
    09188959
  • データ提供元
    CJP書誌  CJP引用  J-STAGE 
ページトップへ